Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Hydroxychloroquine could still prevent COVID-19 and save tens of thousands of lives around the world, say leading scientific researchers. While it doesn’t work in treatment of hospitalised patients, it could still prevent infections. However, fraudulent data, unjustified extrapolation and exaggerated safety concerns together with intense politicisation and negative publicity may stop COPCOV, the only large, global clinical trial testing hydroxychloroquine in COVID-19 prevention, from ever finding out.

Man using an app, with an overlay of the app's user interface © MORU 2020. Photographer: Supa-at (Ice) Asarath.
COPCOV participants will use a mobile app to report their health daily.

COPCOV is a double-blind, randomised, placebo-controlled global study aiming to enrol 40,000 healthcare workers to determine if hydroxychloroquine and chloroquine can prevent COVID-19 that is led by the University of Oxford and the Wellcome supported Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok. 

“There is no guarantee that we’ll soon have a widely available vaccine against COVID-19. Despite all the publicity, we still do not know if hydroxychloroquine can prevent COVID-19, but it’s really important that we find out, one way or the other. The only way to do this is to enrol a large number of participants in randomised controlled trials like COPCOV,” said Sir Jeremy Farrar, Director of the Wellcome Trust.  

Previous prevention studies were too small to show conclusive evidence whether hydroxychloroquine works or not as a preventive. 

“We really don’t know if hydroxychloroquine works or not in prevention or very early treatment. That question remains unanswered. The benefits found in small post-exposure treatment trials although modest could be very valuable if they were confirmed,” said Dr Will Schilling, Co-Principal Investigator of Oxford-led COPCOV clinical trial. 

Early use of hydroxychloroquine could be critical.  

“By the time patients are admitted to hospital virus multiplication is well past its peak and inflammation in the lungs and other complications may prove lethal. At this stage the steroid dexamethasone, which reduces inflammation, saves lives but the antivirals hydroxychloroquine and chloroquine do not,” explained MORU Director Prof Nick Day

“However, that does not rule out that they could be effective much earlier in the illness” explained Prof Day. “Prevention is much easier than cure. The COPCOV study will find out if these drugs can prevent COVID19 or not.” 

Similarly, the scientists say that safety concerns about hydroxychloroquine have been exaggerated.  

“Chloroquine and hydroxychloroquine have a very good safety record in the treatment of malaria and rheumatological conditions over the past 60 years. Billions of treatments have been given. Concerns that they might cause heart arrhythmias are not supported by the evidence from the randomised trials in COVID-19, and in rheumatological conditions hydroxychloroquine has actually been shown to reduce the risk of heart arrhythmias. There is very strong evidence that the doses being evaluated for prevention in the COPCOV study are safe,” said Prof Sir Nick White, COPCOV Co-Principal Investigator.  

------------ 

Press enquiries, contact: John Bleho; +90.537.567.8460 (Mobile/WhatsApp) 

Similar stories

Lack of evidence is key barrier to using portable devices to detect poor quality medicines

A series of papers which reviewed portable devices to detect poor quality medicines has concluded major gaps in scientific evidence remain a key barrier for regulators to implement surveillance systems using such devices.

Tropical Medicine DPhil Students awarded NDM Prize

Every year, the Nuffield Department of Medicine awards NDM Prizes to our most outstanding students. This year, Mo yin and Rebecca Inglis (both at MORU) were highly commended in the category NDM Overall Prize, for conducting research with an outstanding impact. Will Schilling (MORU) received a prize as first year DPhil student, and Mohammad Ali (OCGHR) as second year DPhil student. Our warmest congratulations to you all!

New study alerts to the risk of poor quality medicines used to prevent and treat cardiovascular disease

There are important but neglected issues with substandard and falsified medicines and medical products used to prevent and treat cardiovascular diseases. From limited available data, MORU and IDDO scientists found about one fifth of medicines reported as sampled in the literature were substandard or falsified. This systematic review suggests that more and better quality data and data sharing are needed to better understand the global burden of this problem and inform interventions.

Congratulations new Associate Professors

Following the meeting of the Medical Sciences Divisional Committee to consider applications for the conferral of the title of Associate Professor, we are pleased to announce that Rashan Haniffa, Dorcas Kamuya, Isabella Oyier, Le Van Tan and Timothy Walker have been awarded the title Associate Professor

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.